Regulatory Tracking for WHO Prequalification

Regulatory tracking for WHO prequalification is the disciplined monitoring of WHO PQ guidance, related quality expectations, and customer or donor overlays that affect dossiers, manufacturing sites, testing, and labeling—so suppliers can maintain access to donor and NGO procurement pathways. For many manufacturers of medicines, vaccines, diagnostics, and related health products, WHO PQ is not optional paperwork. It is the gate to market.

Teams that treat PQ as a one-time submission project discover the hard way that guidance, standards references, and assessment expectations move. Late discovery during PQ review—or during requalification—is far more expensive than continuous surveillance with documented disposition.

What is WHO prequalification in operational terms?

WHO prequalification is a quality assessment pathway that helps procurement agencies identify products and manufacturers that meet specified standards. WHO publishes program information, guidance, and product-type procedures through its prequalification channels. Exact modules and evidence expectations depend on product category (for example medicines versus in vitro diagnostics), but the operational pattern is consistent: structured dossier evidence, site quality system fitness, and ongoing obligations after listing.

PQ is not the same as FDA approval, EMA marketing authorization, or a national registration—though those pathways can interact with PQ strategy. Reusing an FDA-only monitoring list and labeling it “PQ-ready” is a category error. Different pathway, different evidence pack, different update streams.

What must teams watch on an ongoing basis?

At minimum, scoped monitoring should include:

1. WHO PQ guidance and procedure updates for your product category.
2. Linked quality system expectations - GMP-related norms, inspection practices, and referenced standards that assessors apply.
3. Dossier-impacting scientific or quality guidance - stability, impurities, labeling, packaging, and testing themes relevant to your products.
4. Site and supply-chain expectations - changes that affect manufacturing sites, contract labs, or key suppliers.
5. Customer and donor overlays - tender requirements that sit on top of WHO baselines (additional certificates, shelf-life, packaging, or language demands).
6. National requirements in manufacturing and destination countries - PQ rarely exists in a vacuum for suppliers who also hold local licenses.

African and other regional suppliers often juggle WHO plus national requirements simultaneously. Consolidation across markets matters—see cross-market compliance consolidation for country-specific updates. SME international strategy context appears in how SMEs meet FDA and international regulatory requirements.

How is WHO PQ tracking different from “reading the website sometimes”?

Occasional website visits optimize for calendar convenience. PQ-relevant changes can land between visits: revised guidance, updated application instructions, or clarified quality expectations. A working program looks like regulatory intelligence for any other high-stakes pathway:

• Scoped sources - WHO PQ pages and documents for your category; linked norms you have committed to in procedures.
• Applicability filter - product families, sites, and dossier modules you actually maintain.
• Impact assessment - which controlled documents, validation packages, or supplier files are candidates for change.
• Disposition - no action, watch, or change—with owner, due date, and evidence.

Without disposition, “we saw it” is not defensible. Assessors and customers ask what you did when expectations shifted. For the general intelligence loop, see what is regulatory intelligence. For QMS handoff, see regulatory change control in a QMS.

What breaks first for smaller suppliers?

Common first breaks:

• Stability and shelf-life narratives that lag updated expectations or climate-zone assumptions used in tenders.
• Labeling and artwork that miss language or information elements required in procurement specs.
• Site quality evidence that does not match current inspection focus areas.
• Supplier and API documentation that is outdated relative to the finished product dossier story.
• Change notification gaps - internal process changes that should have triggered PQ variation or notification logic.

These failures often surface during PQ assessment questions or tender technical evaluation—not during a calm internal surveillance meeting. That timing compresses remediation and increases the chance of lost awards.

How should dual obligations (WHO + national + donor) be modeled?

Use multi-layer tags on each product:

• WHO PQ status and product category procedures.
• National authorizations in manufacturing and key supply countries.
• Donor / procurement overlays by customer or tender family.
• Shared quality system obligations that serve all three.

When a WHO guidance change arrives, score it against PQ modules and against any national licenses that mirror the same quality claims. When a donor tender adds a packaging requirement, do not pretend it is a WHO change—but still track it in the same open-items system so manufacturing and RA see one queue.

Dual-source thinking (external authority vs commercial customer requirements) is analogous to vendor-plus-agency tracking in other sectors—see dual-source regulatory tracking: vendor and agency.

What does a lean PQ surveillance calendar include?

Replace pure quarterly heroics with:

• Continuous or frequent checks of WHO PQ guidance and notices for your category (cadence matched to publication risk, not only meeting convenience).
• A monthly internal triage of new items with mandatory disposition.
• A quarterly governance review of open PQ-impacting changes and tender overlays.
• Event-driven reviews when you change process, site, supplier, or specification.

WHO’s own materials should remain the primary external source—bookmark and monitor through who.int rather than relying only on secondary digests. Digests can help awareness; disposition should cite the primary document.

How do you prove tracking works before the next assessment?

Evidence that impresses both internal auditors and external assessors:

• Source list and owners for PQ-relevant surveillance.
• Disposition records with dates for in-scope updates.
• Change controls or documented N/A rationales linked to those updates.
• Training or procedural updates when expectations hit SOPs.
• A current map of dossier modules and which product families they cover.

If the only artifact is a folder of downloaded PDFs without decisions, you have an archive, not tracking.

FAQ

Is WHO PQ the same as FDA approval?

No. Different pathway, different evidence expectations, different monitoring list. Do not reuse an FDA-only program and call it PQ-ready.

What breaks first for smaller suppliers?

Late discovery of guidance or tender changes that affect stability, labeling, site quality evidence, or supplier documentation—often found during PQ review or technical tender evaluation rather than during internal surveillance.

Do we still need national registrations if we have WHO PQ?

Often yes. PQ supports procurement pathways; national laws and licenses still govern manufacture and many destination markets. Model both explicitly.

How early should tracking start relative to first PQ submission?

Before submission assembly freezes. Baseline monitoring during dossier build prevents writing to outdated guidance, and it establishes the habit you will need for maintenance after listing.